EA201490500A1 - Многослойный высвобождающий состав - Google Patents

Многослойный высвобождающий состав

Info

Publication number
EA201490500A1
EA201490500A1 EA201490500A EA201490500A EA201490500A1 EA 201490500 A1 EA201490500 A1 EA 201490500A1 EA 201490500 A EA201490500 A EA 201490500A EA 201490500 A EA201490500 A EA 201490500A EA 201490500 A1 EA201490500 A1 EA 201490500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
copolymer
composition
peg
combinations
multilayer pressure
Prior art date
Application number
EA201490500A
Other languages
English (en)
Inventor
Жан Поль Ремон
Крис Верват
Original Assignee
Университейт Гент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университейт Гент filed Critical Университейт Гент
Publication of EA201490500A1 publication Critical patent/EA201490500A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение в целом относится к фармацевтической лекарственной форме, содержащей многослойный высвобождающий состав, образуемый посредством соэкструзии. Указанный состав, в частности, включает слой сердцевины, содержащий по меньшей мере один полимер, выбранный из поликапролактона, этилцеллюлозы или их комбинаций, и слой покрытия, содержащий по меньшей мере один сополимер, выбранный из перечня, включающего полиэтиленоксид, полиэтиленгликоль (PEG), сополимер основного бутилированного метакрилата, сополимер поливинилкапролактама, PEG и поливинилацетата и их комбинации.
EA201490500A 2011-08-30 2012-08-30 Многослойный высвобождающий состав EA201490500A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11179362 2011-08-30
PCT/EP2012/066848 WO2013030267A1 (en) 2011-08-30 2012-08-30 Multi-layered release formulation

Publications (1)

Publication Number Publication Date
EA201490500A1 true EA201490500A1 (ru) 2014-06-30

Family

ID=46851427

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490500A EA201490500A1 (ru) 2011-08-30 2012-08-30 Многослойный высвобождающий состав

Country Status (9)

Country Link
US (1) US20140178471A1 (ru)
EP (1) EP2750666B1 (ru)
JP (1) JP2014525423A (ru)
CN (1) CN103764125A (ru)
AU (1) AU2012300908A1 (ru)
BR (1) BR112014004753A2 (ru)
CA (1) CA2846446A1 (ru)
EA (1) EA201490500A1 (ru)
WO (1) WO2013030267A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925270C (en) * 2013-09-27 2021-05-04 Board Of Regents, The University Of Texas System Method of preparation of biodegradable nanoparticles with recognition characteristics
EP3052084A1 (en) * 2013-09-30 2016-08-10 Universiteit Gent Polyurethanes as oral drug delivery platform
WO2017192458A1 (en) * 2016-05-03 2017-11-09 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone or analogs thereof
US20200163446A1 (en) * 2018-11-27 2020-05-28 Colgate-Palmolive Company Oral Care Implement Having a Release Component
EP3886994A1 (en) 2018-11-27 2021-10-06 Colgate-Palmolive Company Oral care implement having a release component

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022962A1 (en) 1994-02-23 1995-08-31 Bm Research A/S Controlled release composition
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
DE19753300A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
TW586944B (en) * 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
FR2818550B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
CA2484632C (en) * 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
GB0222612D0 (en) 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
DE602004026106D1 (de) 2003-11-13 2010-04-29 Psivida Inc Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut
JP2007517776A (ja) * 2003-12-09 2007-07-05 スフェリックス， インコーポレイテッド カテコール官能基を有する生体接着性ポリマー
EP1978940B1 (en) 2006-01-19 2010-12-29 Dow Global Technologies Inc. Biologically active composition comprising ethylcellulose
GB0811024D0 (en) * 2008-06-17 2008-07-23 E Therapeutics Plc Sustained release treatment of depression
CN102159193B (zh) * 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
EP2429492B1 (de) * 2009-05-13 2014-06-25 Basf Se Feste pharmazeutische Zubereitungen enthaltend Copolymere auf Basis von Polyethern in Kombination mit wasserschwerlöslichen Polymeren
US9011912B2 (en) * 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs

Also Published As

Publication number Publication date
BR112014004753A2 (pt) 2017-03-28
EP2750666A1 (en) 2014-07-09
CA2846446A1 (en) 2013-03-07
EP2750666B1 (en) 2017-10-04
WO2013030267A1 (en) 2013-03-07
US20140178471A1 (en) 2014-06-26
CN103764125A (zh) 2014-04-30
AU2012300908A1 (en) 2014-04-17
JP2014525423A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
CL2013003450A1 (es) Composicion que contiene oxintomodulina, un polimero de polietilenglicol y 9-fluorenilmetoxicarbonilo o 2-sulfo-9-fluorenilmetoxicarbonilo; metodos de uso.
CL2014002325A1 (es) Composicion farmaceutica que comprende metformina y un inhibidor de dpp-4 con preferencia linagliptina o un inhibidor de sglt-2 con preferencia 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno; y comprimido de administracion oral.
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
EA201490500A1 (ru) Многослойный высвобождающий состав
WO2008122966A3 (en) A pharmaceutical composition of tacrolimus
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
WO2012095752A3 (en) Personal care compositions
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
CL2014000844A1 (es) Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
WO2015092811A3 (en) Oral films
EP2444073A3 (en) Methods of forming self-supporting films for delivery of therapeutics agents
RS54238B1 (en) ORAL FILM FORMULATIONS CONTAINING DAPOXETINE AND TADALAFIL
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
EP2816114A3 (en) MicroRNAs and uses thereof
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
BR112015000494A2 (pt) matriz e composições da camada para a proteção dos biotivos
RS54475B1 (en) NEW COMBINATION
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан